nach oben

Journal of Thrombosis and Thrombolysis

Erschienen in:

01.11.2012

Thromboprophylaxis in major knee and hip replacement surgery: a review

verfasst von: Gonzalo Eymin, Amir K. Jaffer

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Patients undergoing total knee and total hip replacement (THR/TKR) surgery are at high risk of venous thromboembolism (VTE), and routine thromboprophylaxis is recommended after these procedures. However, current thromboprophylaxis may require daily injections, careful anticoagulation monitoring, and dietary restrictions, which can lead to poor patient compliance and suboptimal outcomes. Therefore, there is an unmet need for simpler medication options. Newer oral anticoagulants have improved efficacy over standard treatments, with convenient dosing regimens, more predictable pharmacologic profiles that reduce the need for anticoagulation monitoring, and fewer drug or food interactions. These drugs have the potential to simplify anticoagulation after THR or TKR surgery, which may lead to improved adherence, thus lowering the incidence of VTE and associated complications after surgery.

FalckYtter Y, Francis CW, Johanson NA et al (2012) Prevention of VTE in orthopedic surgery patients-antithrombotic therapy and prevention of thrombosis, 9th edn. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2):e279S–e325SCrossRef

Geerts WH, Bergqvist D, Pineo GF et al (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8th edn. Chest 133:381S–453SPubMedCrossRef

Spyropoulos AC, Anderson FA Jr, Fitzgerald G et al (2011) Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest 140:706–714PubMedCrossRef

Fanikos J, Piazza G, Zayaruzny M, Goldhaber SZ (2009) Long-term complications of medical patients with hospital-acquired venous thromboembolism. Thromb Haemost 102:688–693PubMed

White RH, Henderson MC (2002) Risk factors for venous thromboembolism after total hip and knee replacement surgery. Curr Opin Pulm Med 8:365–371PubMedCrossRef

Chin PL, Amin MS, Yang KY et al (2009) Thromboembolic prophylaxis for total knee arthroplasty in Asian patients: a randomised controlled trial. J Orthop Surg (Hong Kong) 17:1–5

Yokote R, Matsubara M, Hirasawa N et al (2011) Is routine chemical thromboprophylaxis after total hip replacement really necessary in a Japanese population? J Bone Joint Surg Br 93:251–256PubMedCrossRef

Cohen AT, Skinner JA, Warwick D, Brenkel I (2007) The use of graduated compression stockings in association with fondaparinux in surgery of the hip. A multicentre, multinational, randomised, open-label, parallel-group comparative study. J Bone Joint Surg Br 89:887–892PubMedCrossRef

Edwards JZ, Pulido PA, Ezzet KA et al (2008) Portable compression device and low-molecular-weight heparin compared with low-molecular-weight heparin for thromboprophylaxis after total joint arthroplasty. J Arthroplasty 23:1122–1127PubMedCrossRef

10.

Silbersack Y, Taute BM, Hein W, Podhaisky H (2004) Prevention of deep-vein thrombosis after total hip and knee replacement. Low-molecular-weight heparin in combination with intermittent pneumatic compression. J Bone Joint Surg Br 86:809–812PubMedCrossRef

11.

Arepally GM, Ortel TL (2006) Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 355:809–817PubMedCrossRef

12.

Al Rossaies A, Alkharfy KM, Al Ayoubi F, Al Momen A (2011) Heparin-induced thrombocytopenia: comparison between response to fondaparinux and lepirudin. Int J Clin Pharm 33:997–1001PubMedCrossRef

13.

Friedman RJ, Gallus AS, Cushner FD et al (2008) Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr Med Res Opin 24:87–97PubMed

14.

Deitelzweig SB, Lin J, Kreilick C et al (2010) Warfarin therapy in patients with venous thromboembolism: patterns of use and predictors of clinical outcomes. Adv Ther 27:623–633PubMedCrossRef

15.

van Walraven C, Jennings A, Oake N et al (2006) Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 129:1155–1166PubMedCrossRef

16.

Ansell J, Hollowell J, Pengo V et al (2007) Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the International Study of Anticoagulation Management (ISAM). J Thromb Thrombolysis 23:83–91PubMedCrossRef

17.

Rose AJ, Ozonoff A, Grant RW et al (2009) Epidemiology of subtherapeutic anticoagulation in the United States. Circ Cardiovasc Qual Outcomes 2:591–597PubMedCrossRef

18.

Begelman SM, Hursting MJ, Aghababian RV, McCollum D (2005) Heparin-induced thrombocytopenia from venous thromboembolism treatment. J Intern Med 258:563–572PubMedCrossRef

19.

Smythe MA, Warkentin TE, Stephens JL et al (2002) Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. Am J Hematol 71:50–52PubMedCrossRef

20.

Cuker A (2011) Recent advances in heparin-induced thrombocytopenia. Curr Opin Hematol 18:315–322PubMedCrossRef

21.

Al Rossaies A, Alkharfy KM, Al Ayoubi F, Al Momen A (2011) Heparin-induced thrombocytopenia: comparison between response to fondaparinux and lepirudin. Int J Clin Pharm 33:997–1001PubMedCrossRef

22.

Eriksson BI, Wille-Jorgensen P, Kalebo P et al (1997) A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 337:1329–1335PubMedCrossRef

23.

Turpie AG, Bauer KA, Eriksson BI, Lassen MR (2002) Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 162:1833–1840PubMedCrossRef

24.

Samama MM (2002) Synthetic direct and indirect factor Xa inhibitors. Thromb Res 106:V267–V273PubMedCrossRef

25.

Streiff MB, Haut ER (2009) The CMS ruling on venous thromboembolism after total knee or hip arthroplasty: weighing risks and benefits. JAMA 301:1063–1065PubMedCrossRef

26.

Friedman RJ, Dahl OE, Rosencher N et al (2010) Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res 126:175–182PubMedCrossRef

27.

Stangier J, Clemens A (2009) Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 15(Suppl 1):9S–16SPubMedCrossRef

28.

Eriksson BI, Quinlan DJ, Weitz JI (2009) Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet 48:1–22PubMedCrossRef

29.

Eriksson BI, Dahl OE, Rosencher N et al (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370:949–956PubMedCrossRef

30.

Eriksson BI, Borris LC, Friedman RJ et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358:2765–2775PubMedCrossRef

31.

Eriksson BI, Dahl OE, Rosencher N et al (2007) Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 5:2178–2185PubMedCrossRef

32.

Ginsberg JS, Davidson BL, Comp PC et al (2009) Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 24:1–9PubMed

33.

Kakkar AK, Brenner B, Dahl OE et al (2008) Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372:31–39PubMedCrossRef

34.

Lassen MR, Ageno W, Borris LC et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358:2776–2786PubMedCrossRef

35.

Lassen MR, Raskob GE, Gallus A et al (2009) Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 361:594–604PubMedCrossRef

36.

Lassen MR, Raskob GE, Gallus A et al (2010) Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 375:807–815PubMedCrossRef

37.

Lassen MR, Gallus A, Raskob GE et al (2010) Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 363:2487–2498PubMedCrossRef

38.

Turpie AG, Lassen MR, Davidson BL et al (2009) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373:1673–1680PubMedCrossRef

39.

Romualdi E, Ageno W (2010) Oral Xa inhibitors. Hematol Oncol Clin North Am 24:727–737

40.

Turpie AG, Lassen MR, Eriksson BI et al (2011) Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Thromb Haemost 105(3):444–453PubMedCrossRef

41.

Dahl OE, Quinlan DJ, Bergqvist D et al (2010) A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty. J Thromb Haemost 8(9):1966–1975PubMedCrossRef

42.

Raskob GE, Gallus AS, Pineo GF et al (2012) Apixaban versus enoxaparin for thromboprophlaxis after hip or knee replacement. J Bone Joint Surg Br 94(2):257–264PubMedCrossRef

Titel: Thromboprophylaxis in major knee and hip replacement surgery: a review
verfasst von: Gonzalo Eymin
Amir K. Jaffer
Publikationsdatum: 01.11.2012
Verlag: Springer US
Erschienen in: Journal of Thrombosis and Thrombolysis / Ausgabe 4/2012
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-012-0751-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Eingreifen von Umstehenden rettet vor Erstickungstod!

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2012

Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinician

Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention

Circulating soluble lectin-like oxidized low-density lipoprotein receptor-1 levels predict percutaneous coronary intervention-related periprocedural myocardial infarction in stable patients undergoing elective native single-vessel PCI

Livedoid vasculopathy in a patient with lupus anticoagulant and MTHFR mutation: treatment with low-molecular-weight heparin

Free fatty acids inhibit TM–EPCR expression through JNK pathway: an implication for the development of the prothrombotic state in metabolic syndrome